Management of pediatric plaque psoriasis using biologics.
Adolescent
Algorithms
Biological Products
/ therapeutic use
Child
Child, Preschool
Dermatologic Agents
/ therapeutic use
Humans
Infant
Infant, Newborn
Interleukin-12
/ antagonists & inhibitors
Interleukin-23
/ antagonists & inhibitors
Psoriasis
/ drug therapy
Tumor Necrosis Factor-alpha
/ antagonists & inhibitors
adolescent
biologics
children
monitoring
pediatric
psoriasis
systemic therapy
Journal
Journal of the American Academy of Dermatology
ISSN: 1097-6787
Titre abrégé: J Am Acad Dermatol
Pays: United States
ID NLM: 7907132
Informations de publication
Date de publication:
Jan 2020
Jan 2020
Historique:
received:
03
12
2018
revised:
21
05
2019
accepted:
23
05
2019
pubmed:
1
6
2019
medline:
1
7
2020
entrez:
1
6
2019
Statut:
ppublish
Résumé
Psoriasis is a chronic inflammatory disease with clinical manifestations of the skin that affect adults and children. In adults, biologics have revolutionized the treatment of moderate to severe plaque psoriasis where clear or almost clear is a tangible goal. Research on biologics has recently been extended to children. The introduction of these new therapeutic options has outpaced the limited guidelines in this population. To provide a review of current data on biologics, with a proposal for a clinically relevant treatment algorithm on the management of moderate to severe plaque psoriasis in the pediatric population. A Canadian panel with expertise in psoriasis, pediatric dermatology, and experience with consensus recommendation processes was selected to review the current landscape of pediatric psoriasis and clinical data on biologics plus identify special considerations for baseline workup and monitoring. Recommendations were reviewed and edited by each expert in an iterative process. A treatment algorithm for moderate to severe plaque psoriasis in pediatric patients is presented, incorporating approved biologics. Guidance on baseline screening and ongoing monitoring is also provided. Ultimately, treatment choice depends on the patient and his or her caregiver, with consideration of comorbidities, impact on quality of life, and relevant safety aspects.
Sections du résumé
BACKGROUND
BACKGROUND
Psoriasis is a chronic inflammatory disease with clinical manifestations of the skin that affect adults and children. In adults, biologics have revolutionized the treatment of moderate to severe plaque psoriasis where clear or almost clear is a tangible goal. Research on biologics has recently been extended to children. The introduction of these new therapeutic options has outpaced the limited guidelines in this population.
OBJECTIVE
OBJECTIVE
To provide a review of current data on biologics, with a proposal for a clinically relevant treatment algorithm on the management of moderate to severe plaque psoriasis in the pediatric population.
METHODS
METHODS
A Canadian panel with expertise in psoriasis, pediatric dermatology, and experience with consensus recommendation processes was selected to review the current landscape of pediatric psoriasis and clinical data on biologics plus identify special considerations for baseline workup and monitoring. Recommendations were reviewed and edited by each expert in an iterative process.
CONCLUSION
CONCLUSIONS
A treatment algorithm for moderate to severe plaque psoriasis in pediatric patients is presented, incorporating approved biologics. Guidance on baseline screening and ongoing monitoring is also provided. Ultimately, treatment choice depends on the patient and his or her caregiver, with consideration of comorbidities, impact on quality of life, and relevant safety aspects.
Identifiants
pubmed: 31150699
pii: S0190-9622(19)30860-6
doi: 10.1016/j.jaad.2019.05.056
pii:
doi:
Substances chimiques
Biological Products
0
Dermatologic Agents
0
Interleukin-23
0
Tumor Necrosis Factor-alpha
0
Interleukin-12
187348-17-0
Types de publication
Journal Article
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
213-221Informations de copyright
Copyright © 2019 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.